MedTrace Logo

Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer

NCT04487093 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-07-27

No results posted yet for this study

Summary

Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma. Nearly 80% of lung cancers are diagnosed in an advanced stage (IIIB, and IV) and EGFR mutant non-small cell lung cancer will be resistant after targeted drug treatment. Neoantigen vaccine is a new treatment method for lung cancer, especially for patients with drug resistance.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

neoantigen vaccine + EGFR-TKI

Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks. The targeted drugs are used continuously according to the instructions and dosage until disease progression or intolerance.

DRUG

neoantigen vaccine + anti-angioge

neoantigen vaccine + anti-angioge

Sponsors & Collaborators

  • Tianjin Hengjia Biotechnology Development co., LTD

    collaborator INDUSTRY

  • First Hospital of Shijiazhuang City

    lead OTHER

Principal Investigators

  • Yan Zhang, M.D. · The First Hospital of Shijiazhuang

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-17
Primary Completion
2022-05-17
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04487093 on ClinicalTrials.gov